157 related articles for article (PubMed ID: 11164718)
1. The treatment of undifferentiated neuroendocrine tumors.
Mitry E; Rougier P
Crit Rev Oncol Hematol; 2001 Jan; 37(1):47-51. PubMed ID: 11164718
[TBL] [Abstract][Full Text] [Related]
2. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.
Mitry E; Baudin E; Ducreux M; Sabourin JC; Rufié P; Aparicio T; Aparicio T; Lasser P; Elias D; Duvillard P; Schlumberger M; Rougier P
Br J Cancer; 1999 Dec; 81(8):1351-5. PubMed ID: 10604732
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Rinke A; Gress TM
Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas.
Liu DJ; Fu XL; Liu W; Zheng LY; Zhang JF; Huo YM; Li J; Hua R; Liu Q; Sun YW
World J Gastroenterol; 2017 Jan; 23(3):516-524. PubMed ID: 28210088
[TBL] [Abstract][Full Text] [Related]
9. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
[TBL] [Abstract][Full Text] [Related]
10. [Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases].
Lepère C; Rakotomalala S; Maindrault-Goebel F; Mitry E; Vaillant JN; Julie C; Otmezguine Y; Rougier P
Gastroenterol Clin Biol; 2007 Apr; 31(4):445-7. PubMed ID: 17483787
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
12. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.
Fjällskog ML; Granberg DP; Welin SL; Eriksson C; Oberg KE; Janson ET; Eriksson BK
Cancer; 2001 Sep; 92(5):1101-7. PubMed ID: 11571721
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of neuroendocrine tumors].
Droz JP; Flechon A; Lombard-Bohas C
Rev Prat; 2002 Feb; 52(3):285-9. PubMed ID: 11925719
[TBL] [Abstract][Full Text] [Related]
15. [Neuroendocrine tumors: analysis of 252 cases].
Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Collot T; Fumet JD; Klopfenstein Q; Vincent J; Bengrine L; Ghiringhelli F
Anticancer Res; 2018 Oct; 38(10):5963-5968. PubMed ID: 30275226
[TBL] [Abstract][Full Text] [Related]
17. Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma.
Bajetta E; Catena L; Biondani P; Pusceddu S; Valente M; Bianco N; Novelli E
Anticancer Res; 2014 Oct; 34(10):5657-60. PubMed ID: 25275070
[TBL] [Abstract][Full Text] [Related]
18. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
19. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
20. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]